


| Key | % Net Assets |
|---|---|
| 4.5% | |
| 3.8% | |
| 3.8% | |
| 3.7% | |
| 84.2% |
| Name | % Net Assets |
|---|---|
| GlaxoSmithKline PLC | 4.5% |
| BT Group PLC | 3.8% |
| Royal Dutch Shell PLC (CL B) | 3.8% |
| AstraZeneca PLC | 3.7% |
| Imperial Tobacco Group PLC | 3.1% |
| Unilever PLC | 2.9% |
| British American Tobacco PLC | 2.7% |
| Legal & General Group PLC | 2.2% |
| BG Group PLC | 2.1% |
| RSA Insurance Group PLC | 2.1% |
No asset data available.
| Date | 20-Aug-2025 |
|---|---|
| NAV | 94.67p |
| Currency | GBP |
| Change | 0.20p |
| % | 0.21% |
| YTD change | 8.26p |
| YTD % | 9.56% |
| Fund Inception | 04/10/1999 |
|---|---|
| Fund Manager | Chris White / Ketish Pothalingam |
| TER | 1.38 (30-Mar-2012) |
| Minimum Investment | |
|---|---|
| Initial | £2000 |
| Additional | n/a |
| Savings | n/a |
| Charges | |
|---|---|
| Initial | 3.75% |
| Annual Mang't | 1.25% |
| Exit | n/a |
| Name | % |
|---|---|
| Standard deviation | 0.01 |
| Sharpe ratio | 0.16 |
You are here: research